MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
12.13
-0.93
-7.12%
After Hours: 12.13 0 0.00% 16:01 05/17 EDT
OPEN
13.02
PREV CLOSE
13.06
HIGH
13.02
LOW
12.06
VOLUME
267.89K
TURNOVER
0
52 WEEK HIGH
37.75
52 WEEK LOW
8.08
MARKET CAP
256.91M
P/E (TTM)
-1.9419
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ENTA last week (0506-0510)?
Weekly Report · 6d ago
ENANTA PHARMACEUTICALS INC <ENTA.O>: EVERCORE ISI CUTS TARGET PRICE TO $30 FROM $35
Reuters · 05/09 15:26
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Enanta Pharmaceuticals, Inc. Filed its quarterly results last week. The company's shares are down 8.3% following the results. Revenues of US$17,054,000 beat expectations, but statutory losses grew 13% to US$1.47 per share. The consensus estimate for Enanta's revenues in 2024 is for a decline of 4.4%. The consensus price target held steady at US$20.38 for the company.
Simply Wall St · 05/09 11:56
Enanta Pharmaceuticals, Inc. Quarterly Report on Form 10-Q
Press release · 05/09 04:25
Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Enanta Pharmaceuticals (NASDAQ:ENTA) reported revenues of US$17.1m in the second quarter of 2024. The company's shares are down 4.7% from a week ago. Revenue exceeded analyst estimates by 5.2%. Earnings per share missed estimates by 13%. Revenue is forecast to grow 4.2% in the next 3 years.
Simply Wall St · 05/08 11:49
Buy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor Confidence
TipRanks · 05/08 04:37
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
TipRanks · 05/08 03:58
Enanta Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/07 17:57
More
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.